Deepinder Goyal’s Temple Acquires London-Based Longevous
Deepinder Goyal’s Temple acquires London-based Longevous, bringing its founders on as CMO and Head of Science.
You're reading Entrepreneur India, an international franchise of Entrepreneur Media.
Deepinder Goyal’s wearable startup Temple has acquired London-based longevity medicine practice Longevous for an undisclosed amount, adding clinical and scientific expertise ahead of the launch of its wearable device.
Longevous founders Dr Robert Mohr and Dr Avi Roy, along with their team, will join Temple full-time. Mohr will become Chief Medical Officer; he is a board-certified physician with nearly two decades of clinical experience, having moved from emergency medicine to longevity medicine. Roy will take on the role of Head of Science; he is an Oxford-trained biomedical scientist who co-founded Founders Health and UDA and was previously a research fellow at Oxford’s Centre for the Advancement of Sustainable Medical Innovation.
Longevous, founded in 2025, focuses on preventive and precision medicine, helping clients use science-backed therapies and health data to improve long-term health. It will continue operating as part of Temple, with Mohr and Roy continuing to look after its existing clients.
“We are excited to share that Temple is acquiring Longevous, an evidence-based longevity medicine practice based in London,” said Deepinder Goyal, Founder, Temple. He added that the pair had spent the past few months working with Temple’s science team to test the company’s proprietary metrics and review its research ahead of publication.
Deepinder Goyal’s wearable startup Temple has acquired London-based longevity medicine practice Longevous for an undisclosed amount, adding clinical and scientific expertise ahead of the launch of its wearable device.
Longevous founders Dr Robert Mohr and Dr Avi Roy, along with their team, will join Temple full-time. Mohr will become Chief Medical Officer; he is a board-certified physician with nearly two decades of clinical experience, having moved from emergency medicine to longevity medicine. Roy will take on the role of Head of Science; he is an Oxford-trained biomedical scientist who co-founded Founders Health and UDA and was previously a research fellow at Oxford’s Centre for the Advancement of Sustainable Medical Innovation.
Longevous, founded in 2025, focuses on preventive and precision medicine, helping clients use science-backed therapies and health data to improve long-term health. It will continue operating as part of Temple, with Mohr and Roy continuing to look after its existing clients.
“We are excited to share that Temple is acquiring Longevous, an evidence-based longevity medicine practice based in London,” said Deepinder Goyal, Founder, Temple. He added that the pair had spent the past few months working with Temple’s science team to test the company’s proprietary metrics and review its research ahead of publication.
